Epigenetic experience

Constellation Pharmaceuticals Inc.’s scientific team and deep epigenetics pipeline enabled the company to garner an untranched $100 million venture round.

New investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed Advisors and Sirona Capital participated along with existing investors The Column Group, Third Rock Ventures, Venrock, SR One, the University of California Investment Office, Topspin Partners and Casdin Capital. ...